OncoMark - Supporting Cancer Clinical Decisions & Drug Development.


Welcome to OncoMark Ltd. OncoMark Ltd is an Irish DIAGNOSTICS company founded by Prof. William Gallagher and Mr Steve Penney. Our primary focus is the development of novel panels of cancer biomarkers, to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients. 



Our mission is to build company value by developing and commercializing a portfolio of proprietary oncological prognostic or predictive assays that fill current market gaps and meet clinical needs.


About Us

OncoMark Ltd. is a private company centred on the development and application of biomarker panels, particularly supporting oncology clinical decisions and drug development.

Our lead product in development is a prognostic assay for early stage breast cancer, which utilises the OncoMasTR technology. This technology has potential to be applied in other human cancers where significant unmet needs exist. We are also involved in several active EU grants covering the development of personalised medicine-orientated assays in breast, prostate and colorectal cancers as well as melanoma to feed our product pipeline.

OncoMark is the recipient of several major EU research funding (FP7 and Horizon 2020) awards, which have focused on oncology biomarker research. Our partners include universities, research institutes, clinical oncology groups, spin-outs and large biotech companies. Overall the funding has greatly aided our development from a spin-out entity into a rapidly expanding company with a growing staff of experienced international scientists.